Express Mail Label No. EV 956474505 US Dated: July 6, 2007

Docket No.: AVZ-001CPUSCN2RCE (PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inste Patent Application of: Rima Kaddurah-Daouk et al.

Application No.: 10/718,765 Confirmation No.: 1461

Filed: November 21, 2003 Art Unit: 1639

For: USE OF CREATINE OR CREATINE

ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM

Examiner: J. S. Lundgren

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## **SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)**

## Dear Sir:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicants have not submitted a copy of the cited U.S. patent in accordance with 37 CFR 1.98(a)(2)(ii). Applicants submit herewith copies of foreign patents and non-patent references in accordance with 37 CFR 1.98(a)(2).

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

Application No.: 10/718,765 Docket No.: AVZ-001CPUSCN2RCE

This Information Disclosure Statement, pursuant to 37 CFR 1.114(c), accompanies the Request for Continued Examination (37 CFR 1.114) submitted herewith.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. AVZ-001CPUSCN2RCE.

Dated: July 6, 2007

CMS/SMW/mch

Respectfully submitted,

Cynthia M. Soroos

Registration No.: 53,623

LAHIVE & COCKFIELD, LLP

One Post Office Square

Boston, Massachusetts 02109-2127

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant



stitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known				
Application Number	10/718,765-Conf. #1461			
Filing Date November 21, 2003				
First Named Inventor	Rima KADDURAH-DAOUK			
Art Unit	1639			
Examiner Name	J. S. Lundgren			
Attorney Docket Number	AVZ-001CPUSCN2RCE			

U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code <sup>2</sup> ( if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	A1*	US-4,788,179	11-29-1988	Flohe et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T°
	B1	WO-92/14697-A1	09-03-1992	Cambridge Neuroscience, Inc.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C1	Fitch, Coy D. et al., "A Study of Creatine Metabolism in Diseases Causing Muscle Wasting," Journal of Clinical Investigation, Vol. 43(3):444-452 (1964)	
	C2	Hirst, Marion et al., "Creatine and Rigidity," <i>Quarterly Journal of Medicine,</i> No. 83, pp. 401-418 (1928)	
	СЗ	Pettegrew, Jay W. et al., "Alterations of Cerebral Metabolism in Probable Alzheimer's Disease: A Preliminary Study," <i>Neurobiology of Aging</i> , Vol. 15(1):117-132 (1994)	
	C4	Reinhold, John G. et al., "The Chemical Composition of Voluntary Muscle in Muscle Disease: A Comparison of Progressive Muscular Dystrophy with Other Diseases Together with a Study of Effects of Glycine and Creatine Therapy," <i>J. Clin. Invest.</i> , Vol. 17(4):377-383 (1938)	
	C5	Vis, J.C. et al., "The mitrochondrial toxin 3-nitropropionic acid induces differential expression patterns of apoptosis-related markers in rat striatum," <i>Neuropathology and Applied Neurobiology</i> , Vol. 27:68-76 (2001)	
	C6	Woznicki, Dennis T. et al., "Utilization of Cyclocreatine Phosphate, an Analogue of Creatine Phosphate, by Mouse Brain During Ischemia and Its Sparing Action on Brain Energy Reserves," <i>Journal of Neurochemistry</i> , Vol. 34(5):1247-1253 (1980)	
	C7	European Search Report for Application No. 06011215.8-2107, dated September 18, 2006	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

<sup>1</sup>Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.